Target species
Pig (piglets)
Indications for use
For the prevention of iron deficiency anaemia in piglets.
Contraindications
Do not use in piglets suspected to suffer from deficiency of vitamin E and/or selenium.
Do not use in case of hypersensitivity to the active substance.
Do not use in clinically diseased animals, especially not in case of diarrhoea.
Do not administer intravenously.
Special warnings for each target species
None.
Special precautions for use
Special precautions for use in animals:
It is advisable to stretch the skin at the injection site to minimise leakage after withdrawal of the needle. Normal aseptic injection techniques should be practised. Avoid the introduction of contamination during use.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to the active substance (gleptoferron) or with hemochromatosis should avoid contact with the veterinary medicinal product.
Take care to avoid accidental self-injection and contact with mucous membranes. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after use
Adverse reactions (frequency and seriousness)
Occasionally discolouration of the tissue and/or slight, soft swelling may be observed at the site of injection. This should disappear within a few days. Hypersensitivity reactions can occur. Deaths in piglets following the administration of parenteral iron dextran preparations associated with genetic factors or deficiency of vitamin E and/or selenium have been reported rarely.
Deaths in piglets which have been attributed to an increased susceptibility to infection due to temporary blocking of the reticuloendothelial system, have been reported very rarely.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the
course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals )
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)
Use during pregnancy, lactation or lay
Not applicable.
Interaction with other medicinal products and other forms of interaction
The absorption of concomitantly administered oral iron may be reduced.
Amounts to be administered and administration route
Intramuscular use.
The product is administered as a single 1 ml (200 mg iron) dose by deep intramuscular injection.
Inject once between the 1st and the 3rd day of life.
The use of a multidose syringe is recommended. To refill the syringe use a draw-off needle to avoid excessive broaching of the stopper. The stopper must not be broached more than 10 times.When treating groups of animals in one run, use a draw-off needle that has been placed in the vial stopper to avoid excess broaching of the stopper. The draw-off needle has to be removed after treatment.
Overdose (symptoms, emergency procedures, antidotes)
Large amounts of iron administered by the parenteral route may result in transient reduced capacity of the immune system due to iron overload of lymph macrophages. Pain, inflammation reactions, abscess formation as well as persistent discolouration of muscle tissue at the injection site may occur.
Iatrogenic poisoning may result in the following signs: pale mucous membranes, haemorrhagic gastroenteritis, vomiting, tachycardia, hypotension, dyspnoea, oedema of the limbs, lameness, shock, death, liver damage. Supportive measures such as chelating agents can be used.
Iron overdose can result in gastrointestinal signs such as diarrhoea or constipation.
Treat symptomatically.
Withdrawal period(s)
Meat and offal: Zero days.